Drug intelligence / Profile preview

GRC6211

Development stage: Discontinued
Lead developer: Glenmark Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GRC6211 is a small molecule, orally bioavailable antagonist of the Transient Receptor Potential Vanilloid subtype-1 (TRPV1) receptor. Developed by Glenmark Pharmaceuticals and later licensed to Eli Lilly, it was designed to treat various pain conditions and overactive bladder by blocking nociceptive signaling mediated by sensory neurons. Clinical development reached Phase II for indications such as postoperative dental pain, osteoarthritis pain, and neuropathic pain. However, development was discontinued after Eli Lilly suspended trials in 2008, though the compound remains a tool in scientific research.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on GRC6211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRC6211.

Explore the full profile